Anaplastic Ganglioglioma — Trials

Anaplastic Ganglioglioma — Trials · CancerIndex

Clinical trials

Registered studies

4 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2
Recruiting: 0
Ph III recruiting: 0
Growth YoY: —
Industry share: 50%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (0)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03919071	Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma	active not recruiting	Phase 2	58	National Cancer Institute (NCI)NIH	2	Jul 10, 2026	clinicaltrials
NCT02684058	Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors	completed	Phase 2	151	Novartis PharmaceuticalsINDUSTRY	20	Dec 13, 2023